Cysteinyl Leukotriene Receptor 1 Mediates Ltd4-Induced Activation of Mouse Microglial Cells in Vitro

Shu-ying Yu,Xia-yan Zhang,Xiao-rong Wang,Dong-min Xu,Lu Chen,Li-hui Zhang,San-hua Fang,Yun-bi Lu,Wei-ping Zhang,Er-qing Wei
DOI: https://doi.org/10.1038/aps.2013.130
IF: 7.169
2013-01-01
Acta Pharmacologica Sinica
Abstract:Aim: To investigate the roles of cysteinyl leukotriene receptors CysLT 1 R and CysLT 2 R in leukotriene D 4 (LTD 4 )-induced activation of microglial cells in vitro . Methods: Mouse microglial cell line BV2 was transfected with pcDNA3.1(+)-hCysLT 1 R or pcDNA3.1(+)-hCysLT 2 R. The expression of relevant mRNAs and proteins in the cells was detected using RT-PCR and Western blotting, respectively. Phagocytosis was determined with flow cytometry analysis. The release of interleukin-1β (IL-1β) from the cells was measured using an ELISA assay. Results: The expression of CysLT 1 R or CysLT 2 R was considerably increased in the transfected BV2 cells, and the receptors were mainly distributed in the plasma membrane and cytosol. Treatment of the cells expressing CysLT 1 R or CysLT 2 R with CysLT receptor agonist LTD 4 (0.1–100 nmol/L) concentration-dependently enhanced the phagocytosis, and increased mRNA expression and release of IL-1β. Moreover, the responses of hCysLT 1 R-BV2 cells to LTD 4 were significantly larger than those of hCysLT 2 R-BV2 or WT-BV2 cells. Pretreatment of hCysLT 1 R-BV2 cells with the selective CysLT 1 R antagonist montelukast (1 μmol/L) significantly blocked LTD 4 -induced phagocytosis as well as the mRNA expression and release of IL-1β, whereas the selective CysLT 2 R antagonist HAMI 3379 (1 μmol/L) had no such effects. Conclusion: CysLT 1 R mediates LTD 4 -induced activation of BV2 cells, suggesting that CysLT 1 R antagonists may exert anti-inflammatory activity in brain diseases.
What problem does this paper attempt to address?